73733-75-2

Upstream product

• 5470-18-8 2-Chloro-3-nitropyridine 
• 140-75-0 para-fluorobenzylamine 
• 73733-74-1 N-<(4-fluorophenyl)methyl>-3-nitro-2-pyridinamine 

Downstream Products

• 75971-36-7 ethyl 4-<<<<2-<<(4-fluorophenyl)methyl>amino>-3-pyridinyl>amino>thioxomethyl>amino>-1-piperidine carboxylate 
• 73734-48-2 [3-(4-Fluoro-benzyl)-3H-imidazo[4,5-b]pyridin-2-yl]-(1-phenethyl-piperidin-4-yl)-amine 
• 73733-99-0 ethyl 4-<<3-<(4-fluorophenyl)methyl>-3H-imidazo<4,5-b>pyridin-2-yl>amino>-1-piperidinecarboxylate 
• 73735-72-5 3-<(4-fluorophenyl)methyl>-N-<1-<2-(2-pyridinyl)ethyl>-4-piperidinyl>-3H-imidazo<4,5-b>pyridin-2-amine 
• 73734-78-8 [3-(4-Fluoro-benzyl)-3H-imidazo[4,5-b]pyridin-2-yl]-[1-((E)-3-phenyl-allyl)-piperidin-4-yl]-amine 
• 73735-68-9 3-(4-fluorophenylmethyl)-N-{1-[2-(2-thienyl)ethyl]-4-piperidinyl}-3H-imidazo[4,5-b]pyridin-2-amine 
• 73734-60-8 [3-(4-Fluoro-benzyl)-3H-imidazo[4,5-b]pyridin-2-yl]-[1-(3-phenoxy-propyl)-piperidin-4-yl]-amine 
• 73755-88-1 3-<(4-fluorophenyl)methyl>-N-<1-<2-(4-methoxyphenyl)ethyl>-4-piperidinyl>-3H-imidazo<4,5-b>pyridin-2-amine 
• 73755-85-8 4-{4-[3-(4-Fluoro-benzyl)-3H-imidazo[4,5-b]pyridin-2-ylamino]-piperidin-1-yl}-1-(4-fluoro-phenyl)-butan-1-one 
• 73735-00-9 1-Ethyl-4-(2-{4-[3-(4-fluoro-benzyl)-3H-imidazo[4,5-b]pyridin-2-ylamino]-piperidin-1-yl}-ethyl)-1,4-dihydro-tetrazol-5-one 
• 73735-33-8 1-(3-{4-[3-(4-Fluoro-benzyl)-3H-imidazo[4,5-b]pyridin-2-ylamino]-piperidin-1-yl}-propyl)-1,3-dihydro-benzoimidazol-2-one 
• 98331-33-0 {1-[4,4-Bis-(4-fluoro-phenyl)-butyl]-piperidin-4-yl}-[3-(4-fluoro-benzyl)-3H-imidazo[4,5-b]pyridin-2-yl]-amine 
• 75979-00-9 3-<(4-fluorophenyl)methyl>-N-(4-piperidinyl)-3H-imidazo<4,5-b>pyridin-2-amine 

Relevant academic research and scientific papers

Design, synthesis and characterization of novel N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors leading to the identification of the selective compound, AC1903

The transient receptor potential cation channel 5 (TRPC5) has been previously shown to affect podocyte survival in the kidney. As such, inhibitors of TRPC5 are interesting candidates for the treatment of chronic kidney disease (CKD). Herein, we report the synthesis and biological characterization of a series of N-heterocyclic-1-benzyl-1H-benzo[d]imidazole-2-amines as selective TRPC5 inhibitors. Work reported here evaluates the benzimidazole scaffold and substituents resulting in the discovery of AC1903, a TRPC5 inhibitor that is active in multiple animal models of CKD.

AUTOTAXIN INHIBITORY COMPOUNDS

The present invention relates to compounds of formula I, wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.

New Antihistaminic N-Heterocyclic 4-Piperidinamines. 3. Synthesis and Antihistaminic Activity of N-(4-Piperidinyl)-3H-imidazopyridin-2-amines

To study the bioisosteric replacement of a 2-pyridyl ring for a phenyl nucleus in astemizole, a series of N-(4-piperidinyl)-3H-imidazopyridin-2-amines was synthesised and evaluated.The title compounds were obtained starting from either 8a or 8b by four synthetic methods.The in vivo antihistamine activity was evaluated by the compound 48/80-induced lethality test in rats and the histamine-induced lethality test in guinea pigs after oral and/or subcutaneous administration.Compound 37, the isostere of astemizole, showed the most potent antihistaminic properties in the rat.However, astemizole is superior to 37 as to duration of action and total potency.

N-Heterocyclyl-4-piperidinamines

Novel N-heterocyclyl-4-piperidinamines wherein said heterocyclic radical is an optionally substituted 1H-benzimidazol-2-yl or 3H-imidazo[4,5-b]pyridin-2-yl radical, said compounds being useful as antihistaminic agents.